U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18N4O2
Molecular Weight 298.3397
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRIBEDIL

SMILES

C(N1CCN(CC1)C2=NC=CC=N2)C3=CC4=C(OCO4)C=C3

InChI

InChIKey=OQDPVLVUJFGPGQ-UHFFFAOYSA-N
InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2

HIDE SMILES / InChI

Description

Piribedil is an antiparkinsonian agent which acts as D2 and D3 receptor agonist. In European countries and worldwide it is used as a monotherapy or in combination with dopatherapy for treatment of Parkinson's disease, cognitive impairment and obliterating arteriopathy.

CNS Activity

Originator

PMID

PMID

TitleDatePMID
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
1976 May
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
1977 Jun
Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495).
1978
Age-related mild cognitive deficit: a ready-to-use concept?
2003 Mar
Drug treatment of Parkinson's disease.
2004 Sep
[Modern aproaches to the treatment of early stages of Parkinson disease].
2005
[Dopaminergic and noradrenergic therapy of cognitive impairment].
2006
[The role of pronoran in the therapy of late stage of Parkinson's disease].
2006
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
2006
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
2006 Dec
Pathophysiology and management of syncope in Kearns-Sayre syndrome.
2006 Fall
Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
2006 Jan
Restless legs syndrome: diagnosis and review of management options.
2006 Jun
Activation of D2-like receptors induces sympathetic climactic-like responses in male and female anaesthetised rats.
2006 Jun
Enhancement in dissolution pattern of piribedil by molecular encapsulation with beta-cyclodextrin.
2006 Mar
Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension.
2006 Mar-Apr
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
2006 May-Jun
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
2006 Nov
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
2006 Nov
A reversed-phase high-performance liquid chromatographic method for the determination of zafirlukast in pharmaceutical formulations and human plasma.
2006 Nov-Dec
[Effect of dopamine deficiency on the preparation of visually guided saccadic eye movements].
2006 Sep-Oct
[Cognitive disturbances and dysfunction of neuromediator systems in cerebral vascular insufficiency after treatment with pronoran].
2007
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.
2007
Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
2007 Apr
Impaired cognition and attention in adults: pharmacological management strategies.
2007 Feb
Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency.
2007 Jan 30
About the anti-Parkinson equivalency of levodopa and dopamine agonists.
2007 Jan-Feb
Genetic Contribution of Catechol-O-methyltransferase Polymorphism in Patients with Migraine without Aura.
2007 Mar
Peripheral edema and dopamine agonists in Parkinson disease.
2007 Oct
[Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
2008
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
2008
Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation.
2008 Apr 9
Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
2008 Aug
Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents.
2008 Jul
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.
2008 Sep
Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemissions.
2009 Aug
Ruthenium-catalyzed N-alkylation of amines and sulfonamides using borrowing hydrogen methodology.
2009 Feb 11
Mild cognitive impairment: The dilemma.
2009 Jan
Hallucinations: Etiology and clinical implications.
2009 Jul
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.
2009 Jun 10
Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients.
2009 Sep
Delusional infestation induced by piribedil add-on in Parkinson's disease.
2010 Aug
Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome.
2010 Dec 29
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
2010 Feb 15
Cognitive psychiatry in India.
2010 Jan
Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition.
2010 Jan
Impulse control disorder and piribedil: report of 5 cases.
2010 Jan-Feb
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
2010 Nov
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
2010 Nov 12
Patent

Patent

Sample Use Guides

In Vivo Use Guide
For the treatment of Parkinson's disease as a monotherapy, piribedil should be administered orally at 150 to 250 mg.
Route of Administration: Oral
In Vitro Use Guide
Binding of piribedil to D2, D3 and D4 receptors was measured using [3H]spiperone as a radiolabel. Coronal sections from rat brains were cut at the level of the anterior caudate-putame. The sections were thaw-mounted on gelatin-coated glass slides. Sections were incubated for 5 min in a 50mM Tris-HCl buffer, then were incubated for 30 min at room temperature in the incubation buffer. Piribedil was tested in vitro at 5 different concentrations, from 10 uM to 1 nM.
Name Type Language
PIRIBEDIL
INN   MART.   MI   WHO-DD  
INN  
Official Name English
PIRIBEDIL [INN]
Common Name English
EU-4200
Code English
PIRIBEDIL [WHO-DD]
Common Name English
2-(4-PIPERONYL-1-PIPERAZINYL)PYRIMIDINE
Systematic Name English
TRIVASTAL
Brand Name English
ET-495
Code English
PIRIBEDIL [MI]
Common Name English
PIRIBEDIL [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC N04BC08
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
WHO-VATC QN04BC08
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
Code System Code Type Description
MESH
D010891
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
RXCUI
8353
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY RxNorm
NCI_THESAURUS
C81082
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
MERCK INDEX
M8877
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY Merck Index
ECHA (EC/EINECS)
222-764-6
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
WIKIPEDIA
PIRIBEDIL
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
ChEMBL
CHEMBL1371770
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
CAS
3605-01-4
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
INN
2569
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
EPA CompTox
3605-01-4
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY
PUBCHEM
4850
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY SWITZERF
EVMPD
SUB09908MIG
Created by admin on Tue Mar 06 11:50:35 UTC 2018 , Edited by admin on Tue Mar 06 11:50:35 UTC 2018
PRIMARY